← Back to All US Stocks

BRSYF Stock Analysis - Brainsway Ltd. AI Rating

BRSYF Nasdaq Surgical & Medical Instruments & Apparatus L3 CIK: 0001505065
Recently Updated • Analysis: Mar 21, 2026 • SEC Data: 2026-03-21
AI Rating
HOLD
5% Confidence

📊 BRSYF Key Takeaways

Revenue: N/A
Net Margin: N/A
Free Cash Flow: N/A
Current Ratio: N/A
Debt/Equity: N/A
EPS: $0.00
AI Rating: HOLD with 5% confidence

Investment Thesis

Unable to provide meaningful fundamental analysis due to complete absence of financial data. The company's SEC filings are either unavailable or not properly filed with EDGAR. Without access to income statements, balance sheets, or cash flow data, any investment assessment would be speculative.

BRSYF Strengths

  • + Medical device sector with potential market opportunity
  • + Listed on Nasdaq indicating compliance with exchange standards
  • + Operates in surgical/medical instruments industry with recurring revenue potential

BRSYF Risks

  • ! No financial data available - cannot assess profitability, solvency, or operational efficiency
  • ! Unclear filing status with SEC - potential regulatory or reporting concerns
  • ! Inability to evaluate revenue trends, cash position, or debt obligations creates significant information risk

Key Metrics to Watch

BRSYF Financial Metrics

Revenue
N/A
Net Income
N/A
EPS (Diluted)
$0.00
Free Cash Flow
N/A
Total Assets
N/A
Cash Position
N/A

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

BRSYF Profitability Ratios

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA N/A
FCF Margin N/A

BRSYF vs Healthcare Sector

How Brainsway Ltd. compares to Healthcare sector averages

Net Margin
BRSYF 0.0%
vs
Sector Avg 12.0%
BRSYF Sector
ROE
BRSYF 0.0%
vs
Sector Avg 15.0%
BRSYF Sector
Current Ratio
BRSYF 0.0x
vs
Sector Avg 2.0x
BRSYF Sector
Debt/Equity
BRSYF 0.0x
vs
Sector Avg 0.6x
BRSYF Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

BRSYF Balance Sheet & Liquidity

Current Ratio
N/A
Quick Ratio
N/A
Debt/Equity
N/A
Debt/Assets
0.0%
Interest Coverage
N/A
Long-term Debt
N/A

BRSYF Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

BRSYF SEC Filings

Access official SEC EDGAR filings for Brainsway Ltd. (CIK: 0001505065)

📋 Recent SEC Filings

Date Form Document Action
Nov 13, 2024 SC 13D ea0220999-13dvalor_brain.htm View →
Jun 14, 2023 SC 13G formsc13g.htm View →
Nov 30, 2022 SC 13G sc13g_113022.htm View →
Nov 30, 2022 SC 13G sc13g_113022.htm View →
Feb 14, 2022 SC 13G d9166442_13-g.htm View →

Frequently Asked Questions about BRSYF

What is the AI rating for BRSYF?

Brainsway Ltd. (BRSYF) has an AI rating of HOLD with 5% confidence, based on fundamental analysis of SEC EDGAR filings.

What are BRSYF's key strengths?

Medical device sector with potential market opportunity. Listed on Nasdaq indicating compliance with exchange standards.

What are the risks of investing in BRSYF?

No financial data available - cannot assess profitability, solvency, or operational efficiency. Unclear filing status with SEC - potential regulatory or reporting concerns.

What is BRSYF's revenue and growth?

Brainsway Ltd. reported revenue of N/A.

Does BRSYF pay dividends?

Brainsway Ltd. does not currently pay dividends.

Where can I find BRSYF SEC filings?

Official SEC filings for Brainsway Ltd. (CIK: 0001505065) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is BRSYF's EPS?

Brainsway Ltd. has a diluted EPS of $0.00.

How is the AI analysis conducted?

Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.

Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 21, 2026 | Data as of: 2026-03-21 | Powered by Claude AI